Blood Sample Analysis in Predicting Overall Survival in Patients With Recurrent or Metastatic Head and Neck Cancer

ECOG-ACRIN Cancer Research Group30 enrolled

Overview

RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood sample analysis in predicting overall survival in patients with recurrent or metastatic head and neck cancer.

OBJECTIVES: * To validate the mass spectrometry profile that is predictive of survival benefit in patients with recurrent or metastatic head and neck squamous cell carcinoma treated with EGFR inhibitors. OUTLINE: Plasma and serum samples are analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and classified according to prognosis ("good" vs "poor") using a previously developed predictive algorithm.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Head and Neck Cancer

Interventions

matrix-assisted laser desorption/ionization time of flight mass spectrometryOTHER

Eligibility

Sex: ALLMin age: 18 YearsMax age: 120 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of recurrent or metastatic head and neck squamous cell carcinoma * Meets 1 of the following criteria: * Enrolled on clinical trial ECOG-E3301 and previously treated with irinotecan hydrochloride and docetaxel * Enrolled on clinical trial VU-VICC-HN-0501 and previously treated with docetaxel and bortezomib * Plasma and serum samples available for analysis PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Outcomes

Primary Outcomes

Overall survival measured in weeks

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.